BioIntervene on Monday named Charles Cohen as its chief scientific officer. Cohen was most recently vice president of biology at Xenon Pharmaceuticals (NASDAQ: [[ticker:XENE]]). His experience also includes positions at Vertex Pharmaceuticals (NASDAQ: [[ticker:VRTX]]), Merck (NYSE: [[ticker:MRK]]), and Bayer.
San Diego-based BioIntervene, which recently raised $30 million in a Series A financing round led by MPM Capital, is developing treatments for nerve pain and other chronic inflammatory and neurodegenerative conditions.
Author: Sarah de Crescenzo
Sarah is Xconomy's San Diego-based editor. Prior to joining the team in 2018, she wrote about startups, tech and finance at the San Diego Business Journal. Her decade of full-time news experience includes coverage of subjects including campaign finance, crime and courts as a reporter and editor at outlets throughout California, including the Orange County Register.
She earned a bachelor's degree in English Literature at UC San Diego, where she wrote for the student newspaper and played collegiate lacrosse. In 2019, she earned an MBA at UC Irvine.
View all posts by Sarah de Crescenzo
